To evaluate whether STAT1 Lys637 acetylation could serve as a predictive biomarker for ICB response independent of prior cetuximab exposure, we analyzed an independent cohort of cancer patients with tumor samples collected before ICB treatment. This evidence concerns the gene STAT1 and cancer.